Research
-
Janssen Expands EXPLORER Global Cardiovascular Research Program to Evaluate the Role of XARELTO® in Addressing Critical Medical Needs
New Studies Grow XARELTO® Clinical Development Program to More Than 275,000 Patients -
Janssen Diagnostics Expands Research Portfolio to Include Next-Generation Sequencing
Enhanced Offering to Enable ‘Dynamic Monitoring’ in Cancer Research -
Johnson & Johnson Innovation Catalyzes New and Exciting Science and Technology in Pharmaceutical, Medical Device, Diagnostic and Consumer Healthcare Spaces
Deals span new approaches for cancer, diabetes, autoimmune disease and Alzheimer’s, exciting technologies such as 3-D printing for trauma use, sedation monitoring, cardiac remodeling, probiotics for skin infections -
-
-
-
Johnson & Johnson Innovation Announces Finalists of Cognition Challenge
$100,000 awarded for solutions addressing Alzheimer’s disease and cognitive disorders -
Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
Program Further Extends XARELTO® as the Most Studied New Oral Anticoagulant in the World Today -